Skip to content
Home/Companies/Biotech/BlueRock Therapeutics

BlueRock Therapeutics

Biotech·United States·Exited 2019·Held 3yr
Entry
2016
Hold
3yr
Exit
2019

Who owns BlueRock Therapeutics?

BlueRock Therapeutics is an American Biotech company, now owned by Bayer, which acquired it in 2019 from Leaps by Bayer.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Leaps by Bayer
Investor
Leaps by Bayer
Leaps by Bayer · 2015 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Bayer
Exit Year
2019

More from Leaps by Bayer

Other portfolio companies in the same fund.

Celea Therapeutics
Celea Therapeutics
Active
BiotechUS· 2026
Leaf Agriculture
Active
ClimateTechUS· 2026
Sabanto
Active
AgTechUS· 2026
SonoThera
SonoThera
Active
BiotechUS· 2026
Souffle Therapeutics
Active
BiotechUS· 2025
WellTheory
WellTheory
Active
HealthTechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns BlueRock Therapeutics?

BlueRock Therapeutics is now owned by Bayer, which acquired it in 2019 from Leaps by Bayer.

When did Bayer acquire BlueRock Therapeutics?

Bayer acquired BlueRock Therapeutics in 2019, buying from Leaps by Bayer.

Who did BlueRock Therapeutics sell to?

Leaps by Bayer sold BlueRock Therapeutics to Bayer in 2019 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue